A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses

Kuan-Chieh Ching1,2, Lisa F. P. Ng3–5† and Christina L. L. Chai1,2*†

1NUS Graduate School for Integrative Sciences and Engineering, Centre for Life Sciences, #05-01, 28 Medical Drive, Singapore 117456; 2Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, Level 3, 18 Science Drive 4, Singapore 117543; 3Singapore Immunology Network, A*STAR, 8A Biomedical Grove, Immunos Building, #04-06, Singapore 138648; 4Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Block MD6, Centre for Translational Medicine, 14 Medical Drive, #14-01T, Singapore 117599; 5Institute of Infection and Global Health, University of Liverpool, Ronald Ross Building, 8 West Derby Street, Liverpool L69 7BE, UK

*Corresponding author. Tel: +65-66011061; Fax: +65-67791554; Email: phacllc@nus.edu.sg
†These authors made an equal contribution to this article.

Alphaviruses were amongst the first arboviruses to be isolated, characterized and assigned a taxonomic status. They are globally widespread, infecting a large variety of terrestrial animals, birds, insects and even fish. Moreover, they are capable of surviving and circulating in both sylvatic and urban environments, causing considerable human morbidity and mortality. The re-emergence of Chikungunya virus (CHIKV) in almost every part of the world has caused alarm to many health agencies throughout the world. The mosquito vector for this virus, Aedes, is globally distributed in tropical and temperate regions and capable of thriving in both rural and urban landscapes, giving the opportunity for CHIKV to continue expanding into new geographical regions. Despite the importance of alphaviruses as human pathogens, there is currently no targeted antiviral treatment available for alphavirus infection. This mini-review discusses some of the major features in the replication cycle of alphaviruses, highlighting the key viral targets and host components that participate in alphavirus replication and the molecular functions that were used in drug design. Together with describing the importance of these targets, we review the various direct-acting and host-targeting inhibitors, specifically small molecules that have been discovered and developed as potential therapeutics as well as their reported in vitro and in vivo efficacies.

1. Introduction

1.1 The alphaviruses as human pathogens

Alphaviruses belong to the Togaviridae family, are mainly arthropod-borne viruses that are transmitted by vectors such as mosquitoes and can be found widely throughout the world except Antarctica.1–3 Alphaviruses cause various clinical manifestations ranging from febrile illnesses to neurological diseases.4 Infections with Old World alphaviruses such as Chikungunya virus (CHIKV), Semliki Forest virus (SFV), O’nyong nyong virus (ONNV), Sindbis virus (SV), Mayaro virus (MAYV) and Ross River virus (RRV) commonly cause febrile illness and painful arthralgia or polyarthralgia.5 In contrast, encephalitis is mainly caused by New World alphaviruses such as Venezuelan equine encephalitis virus (VEEV), Eastern equine encephalitis virus (EEEV) and Western equine encephalitis virus (WEEV).6

Functionally, an alphavirus particle comprises a single-stranded positive-sense RNA and delivery system.7 The delivery system involves a protein shell that consists of capsid protein (CP), glycoproteins and a host-derived envelope that is acquired when the virus buds through a cellular membrane.7,8 This protein shell surrounds, stabilizes and protects the positive-sense RNA genome, which encodes non-structural proteins (nsPs) and structural proteins.2 The nsPs (i.e. nsP1, nsP2, nsP3 and nsP4) aid in the production of new viral RNA strands, while the structural proteins consist of the CP, envelope glycoproteins E1, E2, E3 and the residual polypeptide 6K, which ultimately make up part of the mature virion.2 Table 1 illustrates the essential known functions of each alphavirus protein.9

For any given virus, a detailed understanding of the processes involved in its replication cycle is vital for the design of drugs that selectively inhibit viral replication without interfering with host cell function. As illustrated in Figure 1, the replication cycle of alphavirus can be summarized in three main stages, which are virus entry, intracellular replication, and maturation. At the beginning of the replication cycle, alphavirus infects host cells by engaging its E2 glycoproteins with the cell surface receptors and then enters the cells via clathrin-mediated endocytosis.10 As the virus-containing endosome matures, the acidic environment that develops within the endocytotic vesicle destabilizes the envelope glycoprotein structure.11 The resulting conformational change initiates fusion between the virus and late endosomal membranes, leading to the emptying of the nucleocapsid into the cytosol (Event 1).
Table 1. Proteins encoded by alphavirus genome

| Protein | Structural and/or enzymatic functions | Role in virus replication cycle |
|---------|--------------------------------------|---------------------------------|
| nsP1   | membrane association, guanosine-7-methyltransferase (MT), guanylyltransferase (GT) | RNA capping activity |
| nsP2   | nucleotide triphosphatase, helicase, protease | P1234 polyprotein processing |
| nsP3   | macro domain | di-phosphoribose 1’-phosphate phosphatase activity |
| nsP4   | RNA-dependent RNA polymerase | production of viral RNAs |
| CP     | forms nucleocapsid core with the genomic RNA, trypsin-like protease | formation of nucleocapsid |
| E1     | forms part of a continuous isocahedral protein shell on the virion, glycoprotein | mediation of membrane fusion |
| E2     | forms part of a continuous isocahedral protein shell on the virion, glycoprotein | interacts with host cell surface receptors |
| E3     | peripheral glycoprotein | regulates spike assembly |
| 6K     | residual polypeptide chain | assists in E1 folding |

Figure 1. Schematic representation of the replication cycle of alphaviruses. Description of each numbered event indicated in the yellow squares is outlined in the main article text. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Once the nucleocapsid disassembles in the cytosol, the encapsidated genome gains access to the synthetic machinery of the cell and intracellular replication proceeds. Alphaviruses use the cellular machinery for the translation of viral polyprotein P1234 from its full-length genomic RNA. This polyprotein is then processed stepwise into individual nsPs through proteolytic cleavage by nsP2 (Event 2). Early processing of P1234 produces P123 and nsP4, which associate to form the primary replication complex (RC), which performs negative-sense RNA synthesis (Event 3). P123 is further processed to produce the individual nsPs, which associate with nsP4 to form a mature RC (Event 4). The mature RC regulates the synthesis of positive-sense RNA as well as the transcription of subgenomic 26S mRNA using the negative-sense RNA as template (Event 5). Simultaneously, the CP-pE2–6K-E1 structural precursor is also translated from the subgenomic 26S mRNA.

At the maturation stage, the CP is first cleaved from the structural polyprotein by polyprotein processing and assembled with the newly synthesized positive-sense single-stranded RNA molecule to form the nucleocapsid (Events 6 and 7, respectively). The pE2 and E1 molecules are then translocated into the endoplasmic reticulum for post-translational modifications (Event 8). Prior to the arrival of the pE2–E1 heterodimer at the plasma membrane, the pE2 is cleaved to E2 and E3 by furin in the Golgi apparatus to activate the infectivity of the virus. The post-modified envelope glycoproteins then translocate to the plasma membrane and assemble with the mature nucleocapsid. During the budding phase, the assembled virion exits the host cell and acquires a host-derived lipid envelope containing the integral membrane glycoproteins E1 and E2 (Event 9).

1.2 Re-emergence of CHIKV

Prior to 2005, CHIKV was considered a relatively less important viral infection because it was mainly confined to localized outbreaks in Asia and Africa. It was not until 2005–06, when CHIKV re-emerged and caused a large outbreak and infected up to 40% of the population on the French island of La Réunion, that the severity of the nature of CHIKV transmission was realized. The spread of CHIKV was accelerated by increasing globalization, whereby CHIKV was introduced into non-endemic regions by travellers returning from CHIKV-epidemic regions. In <10 years, CHIKV had re-emerged as a global pathogen, spreading from Africa throughout the Indian Ocean Islands, the Pacific Islands and the Americas, causing millions of cases in almost 100 countries. Although death due to CHIKV infection is rare, clinical cases in Asia, especially in countries where health services and procedures are poorly developed, have resulted in high morbidity.

2. Progress towards the development of small-molecule inhibitors of alphaviruses

There is no recognized antiviral therapy to treat alphavirus infections. The current treatment, i.e. administration of non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol, only alleviates the symptoms of the disease. Over the past 50 years, there have been reports on small-molecule alphavirus inhibitors for development as potential antivirals. Nearly half of them were discovered and obtained from natural sources. There are many virus-specific and host targets involved in virus replication that can be targeted by antiviral therapy. Direct-acting inhibitors are designed to act on virus-specific targets, i.e. the nsP(s) and structural protein(s), while host-targeting inhibitors inhibit the functions of host-derived proteins that are actively involved in alphavirus replication. Figure 2 illustrates the list of direct-acting and host-targeting inhibitors and their mechanisms of action in disrupting virus attachment and entry, intracellular replication and virus maturation and budding. Table 2 summarizes the in vitro antiviral properties of these inhibitors described in terms of CC50 (i.e. concentration of inhibitor required for the reduction of cell viability by 50%) and EC50 or IC50 (i.e. concentration of inhibitor required to produce 50% of the total antialphaviral effect) unless stated otherwise.

3. Direct-acting inhibitors

3.1 Inhibitors of virus attachment and entry

Doxycycline, a semi-synthetic tetracycline antibiotic, is commonly used to treat bacterial infections. This drug was discovered to have synergistic in vitro anti-CHIKV effects when administered with ribavirin (i.e. around 3-fold improvement in EC50 values compared with doxycycline or ribavirin alone). Doxycycline inhibited virus attachment and computational studies revealed that doxycycline binds to E2 glycoprotein, hence impairing the important conformational changes of E2 protein for binding to the cell surface receptors. The observed synergistic effects of doxycycline and ribavirin could be due to doxycycline targeting the entry stage and ribavirin targeting the intracellular replication stage.

Arbidol (Figure 3) was originally licensed in Russia for treatment of influenza and other respiratory viral infections. Time-of-addition studies showed that arbidol demonstrated greater antiviral activity against CHIKV when treatment was before infection, suggesting that arbidol blocks the earliest stages of the CHIKV replication cycle (i.e. virus attachment and/or virus entry). Structure–activity relationship (SAR) studies of similar analogues of arbidol were also investigated. Of these analogues, two arbidol tert-butyl ester derivatives, 1 and 2, possessing a sulphoxide group, demonstrated similar activity to arbidol but better cytotoxic profiles (Figure 3). Signs of resistance were observed when cells infected with a mutant CHIKV were treated with arbidol. Since the position of this mutation was localized in the E2 domain, where interactions between E2 and cell receptors occurred, it was believed that arbidol and its derivatives demonstrate anti-CHIKV activity through blocking the interactions between E2 and surface receptors during CHIKV attachment.

Phenothiazine compounds, i.e. chlorpromazine, ethopropazine, methdilazine, perphenazine, thiethylphenazine and thioridazine, are drugs that have been used in the treatment of psychotic and allergy diseases (Figure 3). When these compounds were tested in an entry inhibition assay that employed a heat-sensitive SFV strain (SFVts9-Rluc), an effective inhibition of SFV entry into baby hamster kidney (BHK) cells was observed. One of these phenothiazines, chlorpromazine, has been reported to inhibit HCV entry by blocking the formation of clathrin-coated pits at the plasma membrane for clathrin-mediated endocytosis of viral particles. Hence, it was believed that the inhibition of SFV entry is likely to be the consequence of misassembly of clathrin lattices in the presence of these phenothiazine compounds.
Chloroquine, a commonly used antimalarial drug, has been extensively investigated against viral infections such as HIV.46 This drug demonstrated significant in vitro inhibition of SFV, SINV and CHIKV infections.47–49 The antiviral action of chloroquine involves inhibition of virus entry by increasing the endosomal pH above the critical value needed for the low-pH-dependent fusion reaction to occur, hence preventing the fusion of E1 protein and transfer of virus nucleocapsid into the cytoplasm.47 However, chloroquine was not effective when administered in mice infected with SFV. Instead the drug enhanced SFV replication in vivo and aggravated the disease.50 In addition, results of a double-blind placebo-controlled randomized trial in CHIKV-infected patients did not yield convincing data on its efficacy.51

Obatoclax, an anticancer drug, is an antagonist of the prosurvival Mcl-1 protein, which triggers apoptosis in cancer cells. This drug was screened against alphavirus infections, i.e. SINV, SFV and CHIKV, and demonstrated anti-alphaviral activity at submicromolar concentrations.52 Both time-of-addition and entry inhibition assays showed that this drug had inhibitory activity against SFV entry.52 Mechanistically, this drug neutralizes the acidic environment of the late endosomes and hence inhibits virus fusion.52 In addition, resistance studies after 30 rounds of passaging SFV in the presence of obatoclax obtained a partially resistant mutant that has mutations at the amino residues, i.e. L369 and S395, found in the E1 membrane fusion protein.52

3.2 Inhibitors of virus replication and protein synthesis

Among the [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones that were evaluated in a screening programme against CHIKV infection in vitro, a lead compound, [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one 3 (Figure 3), was identified and found to possess antiviral activity against various CHIKV strains in vitro.53 Interestingly, these small-molecule inhibitors are selective towards inhibition of CHIKV...
Table 2. Biological data of selected small-molecule direct-acting and host-targeting inhibitors

| Compound name | Active against | In vitro efficacy | In vivo efficacy | Reference(s) |
|---------------|----------------|-------------------|-----------------|---------------|
| **Inhibitors of virus entry** | | | | |
| doxycycline | CHIKV | EC₅₀ 10.9 μM against CHIKV replication in Vero cells; EC₅₀ 4.52 μM (with ribavirin) | considerable reduction in pathological signs and virus titre in blood of infected mice | 39 |
| arbidol and its derivatives 1 and 2 | CHIKV | EC₅₀ 30–35 μM against CHIKV-induced CPE in Vero cells | ND | 41,42 |
| phenothiazines | SFV | EC₅₀ 11.3–25.1 μM against SFV replication in BHK cells | ND | 43 |
| chloroquine | CHIKV | IC₅₀ 7.0 μM against CHIKV-induced CPE upon pre-treatment in Vero cells | did not demonstrate clinical efficacy in infected patients | 47,51,148,149 |
| obatoclax | CHIKV | EC₅₀ 0.03 μM against CHIKV replication in BHK cells | ND | 52 |
| | SFV | EC₅₀ 0.11 μM against CHIKV replication in BHK cells | ND | 52 |
| | SINV | virus titre was reduced 5-fold with 0.5 μM in BHK cells | ND | 52 |
| **Inhibitors of virus replication and protein synthesis** | | | | |
| [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one 3 | CHIKV | CC₅₀ >668 μM; EC₅₀ 0.75–2.9 μM against CHIKV replication in Vero cells | ND | 53 |
| | VEEV | EC₅₀ 6.8 μM against VEEV replication in Vero cells | ND | 54 |
| thiazolidinone derivatives 4–8 | CHIKV | IC₅₀ 0.1–10.0 μg/mL against CHIKV-induced CPE in Vero cells | ND | 57 |
| hydrazides 9 and 10 | CHIKV | EC₅₀ 6.3–4.9 μM against CHIKV-induced CPE in Vero cells | ND | 58 |
| hydrazide 11 | CHIKV | CC₅₀ >200 μM; EC₅₀ 1.5 μM against CHIKV replication in BHK cells | ND | 59 |
| peptidomimetic 12 | CHIKV | EC₅₀ 16.4 μg/mL against CHIKV replication in BHK cells | ND | 61 |
| CID15997213 | VEEV | CC₅₀ >25 μM; EC₅₀ 1–2 μM against VEEV-induced CPE in BHK cells | survival rate in infected mice improved from 0% to 60% | 62 |
| ML336 | WEEV | EC₅₀ 10 μM against VEEV-induced CPE in BHK cells | ND | 62 |
| | VEEV | EC₅₀ 0.03 μM against VEEV-induced CPE in BHK cells | survival rate in infected mice improved from 20% to 80% | 63 |
| ID1452-2 | CHIKV | EC₅₀ 31 μM against CHIKV replication in human embryonic kidney (HEK) 293T cells | ND | 65 |
| favipiravir | VEEV | EC₅₀ 7.5 μM against VEEV replication in Vero cells | survival rate in infected mice improved from 20% to 40% | 67,68 |
| | VEEV | EC₅₀ 11 μM against VEEV replication in Vero cells | ND | 68 |
| | EEEV | EC₅₀ 18 μM against EEEV replication in Vero cells | ND | 68 |
| | CHIKV | EC₅₀ 2–12 μM against CHIKV replication in Vero cells | survival rate in infected mice improved from 0% to 60%–80% | 68 |
| MBZM-N-IBT | CHIKV | CC₅₀ >800 μM; EC₅₀ 38.68 μM against CHIKV-induced CPE in Vero cells | ND | 69 |
| secopregnane steroid glycoside 13 | SINV | EC₅₀ 1.5 nM against SINV replication in BHK cells | ND | 70 |
| ribavirin | EEEV | EC₅₀ 2 nM against EEEV-induced CPE in BHK cells | ND | 70 |
| | SFV | EC₅₀ 4.7 μg/mL against SFV-induced CPE in Vero cells | ND | 93 |
| | CHIKV | EC₅₀ 83.3 μg/mL against CHIKV-induced CPE in Vero cells | ND | 93 |

Continued
| Compound name | Active against | In vitro efficacy | In vivo efficacy | Reference(s) |
|---------------|----------------|------------------|-----------------|--------------|
| ribavirin-5'-sulfamate | SFV | IC_{50} 10 µM against SFV-induced CPE in Vero cells | survival rate in infected mice improved from 0% to 92% | 95 |
| 6-azauridine | CHIKV | EC_{50} 0.8 µM against CHIKV replication in chick embryo cells | ND | 93 |
| SFV | EC_{50} 1.6 µM against SFV replication in chick embryo cells | ND | 93 |
| (-)-carbodine | VEEV | EC_{50} 0.3 µg/mL against VEEV-induced CPE in Vero cells | slight, but significant extension in mean time to death was observed after prophylactic treatment | 98 |
| mycophenolic acid | CHIKV | IC_{50} 0.2 µM against CHIKV-induced CPE in Vero cells | ND | 103 |
| harringtonine | CHIKV | EC_{50} 0.24 µM against CHIKV replication in BHK cells | ND | 106 |
| digoxin | CHIKV | EC_{50} 48.8 nM against CHIKV replication in U-2-OS cells; only showed cytotoxic effect at 1 µM | ND | 108 |
| RRV | EC_{50} 126.5 nM against RRV replication in U-2-OS cells | ND | 108 |
| SINV | EC_{50} 198.9 µM against SINV replication in U-2-OS cells | ND | 108 |
| CCG32091 | WEEV | CC_{50} >200 µM; IC_{50} 9.3 µM against WEEV replicon in BSR-T7 cells | ND | 110 |
| indole-2-carboxamide | WEEV | CC_{50} 89.9 µM; IC_{50} 6.5 µM against WEEV replicon in BSR-T7 cells | ND | 111 |
| indole-2-carboxamide | WEEV | CC_{50} 69.9 µM; IC_{50} 0.58 µM against WEEV replicon in BSR-T7 cells | survival rate in infected mice improved from 10% to 30% | 112,113 |
| vEEV | virus titre was reduced 10-fold with 2.5 µM in BE(2)-C cells | ND | 113 |
| anthranilamides | VEEV | CC_{50} >75 µM; IC_{50} 0.56–1.6 µM against WEEV replicon in BSR-T7 cells | ND | 114 |
| Inhibitors of virus maturation | VEEV | virus titre was reduced 10-fold with 25 µM in HEK293 cells | ND | 114 |
| dioxane-based compound | SINV | CC_{50} >1 mM; EC_{50} 1–3.4 µM against CHIKV replication in BHK cells | ND | 72,73 |
| picolinic acid | CHIKV | viral load was reduced by up to 2 logs with 2 mM in Vero cells | ND | 75 |
| Inhibitor of multiple stages of virus replication cycle | CHIKV | CC_{50} >700 µM in BHK cells and U2OS cells; EC_{50} 79–80 µM against CHIKV CPE in Vero cells | showed reduced viral burden and decreased foot swelling in infected mice | 78,79,81 |
| suramin | SFV | EC_{50} 40 µM against SFV-induced CPE in Vero cells | ND | 79 |
| SINV | EC_{50} 141 µM against SINV-induced CPE in Vero cells | ND | 79 |
| Modulators of cellular functions that assist virus replication | WP1130 | virus titre was reduced by nearly 2 logs after pretreatment with 5 µM in Vero cells | ND | 120 |
| WP1130 derivatives | SINV | virus titre was reduced by nearly 2 logs after pretreatment with 5 µM in Vero cells | ND | 121 |
| Ag-126 | VEEV | virus titre was reduced by 4 logs after pretreatment with 10 µM in U87MG cells | ND | 123 |
| EEEV | virus titre was reduced by 1 log after pretreatment with 10 µM in U87MG cells | ND | 123 |
| WEEV | ND | ND | 123 |
Table 2.  Continued

| Compound name     | Active against | In vitro efficacy | In vivo efficacy | Reference(s) |
|-------------------|----------------|-------------------|-----------------|--------------|
| berberine         | CHIKV          | virus titre was reduced by 2 logs after pretreatment with 10 µM in U87MG cells | showed reduced joint inflammation in infected mice | 126          |
|                   | ONNV           | CC₅₀ 202.6 µM; EC₅₀ 4.5 µM against CHIKV replication in HEK 293T cells | ND             | 126          |
|                   | SFV            | virus titre was reduced by nearly 4 logs with 3 µM in BHK cells | ND             | 127          |
|                   | SINV           | virus titre was reduced by 3–4 logs with 3 µM in BHK cells | ND             | 127          |
|                   | CND0335 and CND3514 | CC₅₀ >50 µM; EC₅₀ 2.2–3.3 µM against CHIKV-induced CPE in HuH–7 cells | ND             | 128          |
| SKI-417616        | SINV           | virus titre was reduced by over 3–5 logs with 10 µM in HEK293 cells | ND             | 122          |
| leptomycin B      | VEEV           | virus titre was reduced by 5 logs after pretreatment with 45 nM in U87MG cells | ND             | 140          |
| KPT-185, KPT-335 and KPT-350 | VEEV | CC₅₀ >10 µM; EC₅₀ 0.09–0.62 µM against VEEV replication in Vero cells | ND             | 141          |
| bortezomib        | VEEV           | virus titre was reduced by 4 logs after pretreatment with 0.1 µM in U87MG cells | ND             | 143          |
|                   | WEEV           | virus titre was reduced by 4 logs after pretreatment with 0.1 µM in U87MG cells | ND             | 143          |
|                   | EEEV           | virus titre was reduced by 3 logs after pretreatment with 0.1 µM in U87MG cells | ND             | 143          |

ND, not determined.

replication and not of related viruses, such as SINV and SFV. Delang et al. discovered that compound 3 demonstrates inhibition of CHIKV replication at a post-entry step, other than viral protein translation or viral RNA synthesis. Since they could not obtain enzymatically active CHIKV nsP1, they investigated the mechanism of 3 against VEEV nsP1 and results showed that 3 inhibited the activity of VEEV nsP1, specifically the in vitro guanylyltransferase (GT) activity, hence causing significant inhibition of VEEV replication. In addition, a CHIKV mutant possessing a P34S substitution in nsP1 was also found to be highly resistant to the antiviral effect of compound 3.

S-Adenosyl methionine (AdoMet) and S-adenosyl homocysteine (AdoHcy) are natural substrates of alphavirus nsP1 mRNA capping machineries. Being an analogue of AdoMet and AdoHcy, sinefungin has been shown to be a potent inhibitor of RNA capping activities. Sinefungin was evaluated against methyltransferase (MT) and GT activities in VEEV nsP1 in an enzymatic assay and demonstrated reasonably good activities against MT and GT. As demonstrated in the studies, sinefungin is likely to function at two levels, i.e., it inhibits methyltransfer by competing with the methyl donor, AdoMet, and blocks the activation of AdoHcy in the GT reaction.

In the past decade, small-molecule inhibitors of CHIKV replication with inhibitory effects against nsP2 have been reported. Thiazolidinones, i.e., compounds 4–8 (Figure 3), demonstrate antiviral activities against CHIKV and limited cytotoxic liabilities at their active concentrations. A molecular docking study revealed that these inhibitors established crucial hydrophobic interactions with S2 and S3 pockets of CHIKV nsP2 and hydrogen bonding interactions with a key residue (Tyr1047), suggesting that these thiazolidinone derivatives could be inhibitors of CHIKV nsP2 protease.

In another strategy for small-molecule drug discovery, a virtual screening method was utilized. A homology model of CHIKV nsP2 based on a VEEV nsP2 protease template was created and screened with a commercially available library of ~5 million compounds for binding activities with the protease active site. Of these, compound 9 (Figure 3), which possesses a hydrazide structure, demonstrated significant inhibition in both virus yield and CHIKV-induced cytopathic effect (CPE) reduction assays. Using hydrazide 9 as a lead, an SAR approach was adopted by designing and evaluating a series of hydrazide compounds. Replacement of the cyclopropane ring in hydrazide 9 with an alkene moiety resulted in hydrazide 10 (Figure 3), which demonstrated a slightly improved antiviral profile. A new class of hydrazide-based nsP2 inhibitors was also designed and generated by employing computational pharmacophoric replacement and using hydrazide 9 as a lead. Of these, hydrazide 11 (Figure 3) not only showed inhibition of the cleavage of peptide substrate by CHIKV nsP2 in a fluorescence resonance energy transfer (FRET)-based cell-free protease assay, but also demonstrated anti-CHIKV activities at micromolar concentrations. Interestingly, reduction of both viral RNA synthesis.
and infectious virus production was observed when cells were pre-
treated with hydrazide 11, suggesting there could be other modes
of action associated with this compound. Moving forward, it
would be interesting to analyse the inhibitory properties of the indi-
vidual cis/trans isomers of hydrazide 11 as stereochemistry could
be a major determinant of compound activity.

A peptidomimetic strategy was also employed in the design of
small-molecule inhibitors of CHIKV nsP2 in which these peptidomi-
metic inhibitors were modified from specific amino acid se-
quences, such as Ala1861-Gly1862-Gly1863-Tyr1864 (AGGY),
which is the natural substrate of CHIKV nsP2 protease. The
studies led to the identification of peptidomimetic 12 (Figure 3),
which demonstrated a maximum of 100% inhibition of CHIKV rep-
lication at 68.2 μg/mL concentration. Molecular modelling re-
vealed that peptidomimetic 12 binds to CHIKV nsP2 via covalent
interaction between its α-β unsaturated ketone functionality and
the catalytic residue S1013 in nsP2.

Quinazolinone compound CID15997213 (Figure 3) demon-
strates potent in vitro activity against various VEEV strains (TC-83
and V3526) and WEEV as well as good in vivo antiviral efficacy.
A mutation at two key residues (Y102C and D116N) in the N-ter-
mal region of nsP2 in a drug resistance study indicated that the

Figure 3. Chemical structures of selected direct-acting inhibitors. Inhibitors of virus attachment and entry: arbidol and its derivatives 1 and 2 and
phenothiazines. Inhibitors of virus replication: compounds 3–12, CID15997213, ML336, ID1452-2, favipiravir, MBZM-N-IBT and seconpregnane steroid
glycoside 13 are inhibitors of virus replication. Inhibitors of virus maturation: compound 14 and picolinic acid.
site of action of CID15997213 could be the nsP2 domain.\textsuperscript{62} CID15997213 was utilized as a starting point for a classical structure–activity optimization study due to its preliminary promising antiviral activity and good physiochemical profile. In the study, amidine ML336 (Figure 3) was identified as possessing nearly a 7-fold improvement in antiviral potency over the best quinazolinone-based analogues and good in vivo efficacy.\textsuperscript{63} Mechanistic studies using mutant VEEV, which carried a mutation in nsP2, showed that ML336 possibly targets a critical function of nsP2/nsP4 in the VEEV RC, and hence inhibits viral replication.\textsuperscript{63}

nsP2 is not only involved in viral RNA synthesis by being a cofactor of the RC, but it is also a virulence factor that blocks cellular gene transcription, i.e. transcriptional shutoff by inducing the degradation of the Rpb1, a catalytic subunit of RNA polymerase II.\textsuperscript{64} Employing a high-throughput phenotypic functional assay to identify small molecules targeting nsP2-mediated transcriptional shutoff, a natural product derivative, DJ1452-2 (Figure 3), which partially blocks nsP2 activity and inhibits CHIKV replication in vitro, was identified when screened with a chemical library of 3040 molecules.\textsuperscript{65}

Favipiravir, an analogue of pyrazine (Figure 3), has been reported to have broad-spectrum antiviral activity against various RNA viruses, including WEEV and CHIKV.\textsuperscript{66} Favipiravir not only demonstrated potent in vitro and in vivo activities against CHIKV and WEEV infections,\textsuperscript{67,68} but also demonstrated inhibitory activities against CHIKV RNA synthesis in \( ^{3} \text{H} \)uridine labelling experiments.\textsuperscript{68} A phenotypic resistance to favipiravir was also observed when cells were infected with a mutant CHIKV genotype (with a K291R mutation in CHIKV nsP4). This suggests that favipiravir possibly inhibits CHIKV replication via interference with RNA-dependent RNA polymerase (RdRp) activity.\textsuperscript{69}

A molecular hybrid of isatin-\( \beta \)-thiosemicarbazone and benzimidazole, MB2M-N-IBT (Figure 3), was developed for investigation against in vitro CHIKV infection.\textsuperscript{69} This hybrid compound not only reduced viral protein and RNA production at 200 \( \mu \text{M} \) concentration, but also inhibited CHIKV infection in the early and late phases of replication, which indicates multiple mechanisms for its anti-CHIKV activity.\textsuperscript{69} In addition, molecular docking studies revealed favourable binding affinities of MB2M-N-IBT with the homology models of CHIKV nsP1, nsP3 and nsP4.\textsuperscript{69}

A class of natural products (i.e. secopregnane steroid glucogenin C and its monosugar-glycoside cynamataside A of Strabilanthes cusia and three new pentasugar glycosides of glucogenin C of Cyananchum paniculatum) were found to possess effective inhibition against alphaviruses such as SINV and EEEV at nanomolar concentrations.\textsuperscript{70} These steroidal-containing compounds, including secopregnane steroid glycoside 13 (Figure 3), suppress the expression of SINV subgenomic RNA (sgRNA), predominantly without affecting the accumulation of viral genomic RNA.\textsuperscript{70} From the study, the mode of action of these compounds may involve alteration of the structure of the sgRNA promoter, thereby affecting the binding of the transcription complex to the sgRNA promoter, resulting in a decreased expression of sgRNA.\textsuperscript{70}

3.3 Inhibitors of virus maturation

Dioxane was discovered as a suitable ligand that bound nicely to the hydrophobic pocket of the SINV CP in protein crystallization studies.\textsuperscript{71} Employing the crystal structure of this hydrophobic pocket in a molecular docking study, a series of dioxane-based antivirals that were predicted to bind to the hydrophobic pocket were synthesized and evaluated against SINV replication.\textsuperscript{72,73} Although the most potent dioxane-based compound, 14 (Figure 3), demonstrated inhibition against SINV replication, it did not demonstrate any inhibition of the nucleocapsid assembly in the CP assembly assay.\textsuperscript{72,73}

Picolinic acid (PCA; Figure 3) was previously reported to have antiviral properties against HIV and human herpes simplex virus.\textsuperscript{74} In a molecular docking study, PCA showed stronger binding affinity with the conserved hydrophobic pocket of homology-modelled CHIKV CP as compared with dioxane.\textsuperscript{75} PCA also showed strong binding affinity with purified CHIKV CP in isothermal titration calorimetry, surface plasmon resonance and fluorescence spectroscopy studies.\textsuperscript{75} PCA was non-toxic up to 2 mM and demonstrated anti-CHIKV activity by causing significant inhibition of viral RNA production and plaque formation at 2 mM concentration.\textsuperscript{75} Taking these findings together, PCA may inhibit CHIKV maturation via interfering with CP formation.

3.4 Inhibitor of multiple stages of virus replication cycle

Suramin, a symmetrical sulphonated naphthylurea compound, was first used as an anti-parasitic agent for the treatment of African trypanosomiasis in the 1920s. Since then, research on suramin has gained momentum after its anticancer and antiviral potential was discovered between the 1970s and 1990s.\textsuperscript{76,77} Its antiviral activity against CHIKV, SFV and SINV was recently demonstrated.\textsuperscript{78,79} Suramin restricted CHIKV multiplication via inhibition of CHIKV RNA synthesis.\textsuperscript{79} Furthermore, various studies also demonstrated that suramin interferes with post-attachment stages of the CHIKV replication cycle (i.e. virus entry or the fusion step).\textsuperscript{78,79} An SAR study on suramin showed that removal of any moieties from suramin resulted in a loss of activity or 3- to 10-fold drops in activities.\textsuperscript{79} A molecular docking study showed that suramin docks in the cavity between CHIKV E1 domain II and E2 domain C. This interaction may inhibit the process of virus release, resulting in reduced cell–cell transmission.\textsuperscript{78} Treatment with suramin was shown to reduce viral loads as well as reducing foot swelling, inflammation and cartilage damage in CHIKV-infected C57BL/6 mice.\textsuperscript{81} The clinical efficacy of suramin in ameliorating CHIKV-induced arthritis in patients would be worth exploring in the near future.

4. Host-targeting inhibitors

4.1 Inhibitors of virus entry

5-Nonyloxytryptamine (5-NT; Figure 4), a C5 unbranched nonyl-substituted serotonin, has been shown to possess affinity for most serotonin receptors.\textsuperscript{82} In antiviral evaluation studies against in vitro reovirus infection, 5-NT impeded virus entry and delayed intracellular transport of incoming virions by affecting the distribution of early endosomes, thereby leading to an inhibition of virus infection.\textsuperscript{83} 5-NT exhibited potent anti-CHIKV activity,\textsuperscript{83} which strongly suggests that serotonin receptor signalling could be one of the crucial regulatory factors involved in the entry of viruses of diverse families, including CHIKV.

Synthetic flavaglines (i.e. FL23 and FL3) and sulfonyl amidine 1 m are known to bind to host cellular receptors such as prohibitin (PHB),\textsuperscript{84,85} which a number of different pathogens, including CHIKV, dengue virus (DENV) and HIV, use for entry into the host
These compounds (Figure 4) were assessed for antiviral evaluation on CHIKV production in PHB-expressing cells, and significantly reduced CHIKV production. In addition, co-localization studies between PHB and CHIKV in the presence of these compounds showed interference in CHIKV E2-PHB binding.

4.2 Inhibitors of virus replication and protein synthesis

Nucleoside analogues (containing sugars such as ribose or deoxyribose) are by far the most important class of antiviral drugs. Ribavirin (Figure 4) was one of the first anti-alphaviral inhibitors reported when it was shown to reduce SFV-induced CPE in chick embryo fibroblasts. This compound was once considered as a treatment for alphaviral infections when studies showed that the combination of IFN-α and ribavirin had a subsynergistic antiviral effect on CHIKV and SFV replication. A number of mechanisms associated with ribavirin have been proposed. Of these, the predominant mechanism of action is inhibition of inosine-5’-monophosphate dehydrogenase (IMPDH), which leads to a depletion of cellular GTP pools and is needed for virus replication. A derivative of ribavirin, ribavirin-5’-sulfamate (Figure 4), was also described to inhibit SFV replication. Another nucleoside analogue, 6-azauridine (Figure 4), is a broad-spectrum antimetabolite that inhibits both DNA and RNA virus replication of CHIKV and SFV, while replacement of the adenine or guanine core in a nucleoside with 4-fluoroimidazole resulted in 5-fluoro-1-β-D-ribofuranosylimidazole-4-carboxamide (5-FICAR; Figure 4), which showed antiviral activity against SINV.

The carbocyclic analogue of cytidine, carbodine (Figure 4), has been shown to deplete CTP pools by inhibiting CTP synthetase (which converts UTP into CTP) and thereby inhibits DNA synthesis during the replication cycle of a range of DNA and RNA viruses. Two enantiomeric...
pure carboline compounds [(+)-carboline and (−)-carboline] were screened against VEEV-induced CPE.98 Interestingly, (+)-carboline did not exhibit any activity whereas (−)-carboline demonstrated potent in vitro and in vivo antiviral efficacy.98 Cordycepin (3′-deoxyadenosine; Figure 4) is known to influence replication of several viruses via reducing the poly(A) content of viral mRNA.99,100 However, antiviral studies against SFV infection demonstrated that cordycepin did not specifically inhibit the synthesis of poly(A) sequences; instead it inhibited the synthesis of the virus PC.101

Mycophenolic acid (Figure 4), a weak organic acid and well-known immunosuppressive agent, was first isolated from the fungus Penicillium stoloniferum and demonstrated broad-spectrum antiviral activity against replication of several viruses, including CHIKV.102,103 Similar to ribavirin, the mechanism of action of mycophenolic acid in vitro is based on inhibition of cellular IMPDH activity.104 Brefeldin A, a macrolide lactone antibiotic produced by the fungus Eupenicillium brefeldianum, inhibits SINV protein synthesis and RNA replication, possibly due to its interference with the formation of vesicles that were required for viral RNA synthesis.104

Harringtonine (Figure 4), a cephalotaxine ester derived from the Japanese plum yew, Cephalotaxus harringtonia, is known to be an inhibitor of eukaryotic protein synthesis.105 It not only demonstrated dose-dependent inhibition of CHIKV during the early events of CHIKV replication after virus entry, but significantly reduced CHIKV RNA and the synthesis of nsP3 and E2 proteins at its non-cytotoxic concentrations (1 or 10 μM).106 The mechanism of action of harringtonine has been suggested not to be specific to CHIKV, instead being exercised through inhibition of the eukaryotic large ribosomal unit, thereby suppressing viral protein translation, leading to a decrease in the levels of RCs and viral RNA.106

Lanatoside C, an approved cardiac glycoside that acts by inhibiting the Na+-K+-ATPase ion pump, was demonstrated to have potent inhibitory activity against various RNA viruses, such as DENV, CHIKV and SINV.107 As optimum levels of intracellular Na+ and K+ in the cytosol environment are important for proper replication of various DNA and RNA viruses, increased levels of intracellular Na+ and reduced intracellular K+ caused by lanatoside C affected the replication of CHIKV and SINV.107 Similarly, another inhibitor of the Na+-K+-ATPase ion pump, digoxin (Figure 4), showed enhanced inhibition of CHIKV when extracellular Na+ was introduced, but exhibited no or marginal inhibition of CHIKV when extracellular K+ was introduced.108 Digoxin displayed a broad-spectrum inhibitory effect against other alphaviruses, such as RRV and SINV.108 In addition, mutation of the valine at residue 209 in nsP4 to isoleucine was observed in digoxin-resistant CHIKV populations, suggesting that digoxin could be inhibiting CHIKV replication by disrupting RNA synthesis.108 Although digoxin is known to be cytotoxic owing to its narrow therapeutic index in treating heart diseases,109 the observed in vitro CHIKV inhibition by digoxin was not due to its cytotoxicity (i.e. toxicity only occurred at a dose 20 times its EC50 for antiviral activity).108 Preclinical studies using an in vivo mouse model might be employed to verify the margin between its toxicity and antiviral efficacy.

To improve the poor in vitro metabolic properties of the reported inhibitor of WEEV, thieno[3,2-b]pyrrole CCG32091 (Figure 4),110 a class of indole compounds, i.e. bioisosteres of thieno[3,2-b]pyrrole, was evaluated for activity against the WEEV replicon.111 The investigation led to the discovery of an indole analogue, (R)-enantiomer 15 (Figure 4), which not only possesses better metabolic stability in mouse liver microsomes (MLMs) as compared with CCG32091 (half-life 31 versus 1.7 min), but also potent antiviral activities, a good cytotoxic profile and in vivo efficacy.111 In subsequent SAR studies, various structural modifications, such as varying substituents at the N1 and C2 position of the indole core as well as scaffold hopping (i.e. replacement of the indole with pyrrole, benzimidazole and imidazole), were made.112 The investigation led to the discovery of indole-2-carboxamide 16 (with a C2 terminal pyridinyl group; Figure 4), which exhibited 10-fold improvement in potency as compared with 15 in a WEEV replicon assay.112 Mechanistically, both classes of thieno[3,2-b]pyrrole and indole compounds, i.e. CCG32091 and 16, did not directly inhibit WEEV RdRp or other viral enzymatic activities; instead they possibly targeted a host factor that modulates a cellular cap-dependent translation pathway such as the eukaryotic initiation factor 2b signalling pathway.113

Continuing the efforts to improve the physiochemical properties that contribute to the in vivo blood–brain barrier (BBB) permeability of indole 16, the indole core was replaced with a lower molecular weight core structure such as pyrrole or a simple phenyl ring.114 Through these efforts, two anthranilamide analogues, 17 and 18 (Figure 4), were discovered as possessing better metabolic stability in MLMs (half-life 15–19 versus 9 min), improved aqueous solubility and nearly equivalent passive permeability as measured in a BBB–parallel artificial membrane permeability assay without losing anti-WEEV potency.114

4.3 Inhibitors of virus maturation

Earlier reports showed that during alphavirus maturation the envelope glycoprotein precursor, pE2, is usually cleaved at short multi-basic motifs by furin or furin-like convertases.115–117 To inhibit the maturation of CHIKV virions, a synthetic peptide mimic of the conserved sequence (KR)(X)(KR)(R), of the cleavage site of CHIKV pE2, namely decanoyl-RVRK-chloromethyl ketone (FI), was screened for anti-CHIKV activity. This peptidomimetic behaved like furin inhibitors, which induce inhibition of CHIKV infection by preventing the processing of pE2.118 Interestingly, FI also showed inhibition of CHIKV entry when used as a pretreatment, suggesting there could be other modes of action associated with FI.118

4.4 Modulators of cellular functions that assist virus replication

Deubiquitinases (DUBs) are a class of cysteine proteases involved in proteasomal degradation and regulation of cellular processes such as the unfolded protein response.119 Studies showed that many viruses depend on the ubiquitin (Ub) cycle by hijacking cellular Ub-modifying enzymes, including DUBs, to assist their post-entry events.119 To investigate the relationship between DUBs and virus infection, an inhibitor of DUB, WP1130 (Figure 5), was evaluated to determine whether DUBs promoted norovirus infection.120 Results showed that WP1130 inhibited a proteasome-associated DUB known as USP14 and restricted replication of several RNA viruses, including SINV, through the IRE1-dependent decay of viral proteins, which was activated upon inhibition of DUBs.120 Derivatives of WP1130 possessing fluoro-substitution or no substitution on the pyridinyl group and a solubilizing group on the phenyl group were explored to improve the aqueous solubility.
of WP1130.\textsuperscript{121} Of these, derivatives 19 and 20 (Figure 5) significantly reduced virus titres in SINV-infected Vero cells.\textsuperscript{121}

The mitogen-activated protein (MAP) signalling pathway has been suggested to be activated by viruses, which potentially confers a prosurvival status on the infected cells in order to have a productive infection cycle for generating sufficient progeny virions.\textsuperscript{122–125} For this reason, an inhibitor of the MAP kinase, extracellular signal-regulated kinase (ERK), Ag-126 (Figure 5), was evaluated and found to possess inhibitory activity against VEEV replication in its non-toxic concentration range during early and late events of the virus replication cycle.\textsuperscript{123} Another natural product, berberine (Figure 5), was also found to impede alphavirus replication through inhibiting the phosphorylation of ERK, thereby affecting the egress of progeny virions, since it did not affect virus entry and enzymatic activity of the viral RC.\textsuperscript{126} In vivo antiviral efficacy studies of berberine revealed that it could behave as both an antiviral agent (i.e. reducing viral load in infected mice) and an anti-inflammatory agent (i.e. decreasing joint swelling in infected mice).\textsuperscript{126} Interestingly, berberine demonstrated broad-spectrum antiviral activity against other Old World alphaviruses such as SINV and SFV,\textsuperscript{127} while Ag-126 demonstrated broad-spectrum antiviral activity against New World alphaviruses such as EEEV and WEEV.\textsuperscript{123} On the other hand, a kinase inhibitor library containing 4000 compounds was screened against \textit{in vitro} CHIKV infection and among the 72 primary hits, 6 compounds containing benzofuran, thiazole and pyrrolopyridine core structures were identified. Of these, the benzofuran CND0335 and pyrrolopyridine CND3514 (Figure 5) exhibited significant reduction in virus titres at 20 \textmu M.\textsuperscript{128}

Activation of the D4 dopamine receptor generates a series of downstream signals in which phosphorylation of ERK occurs, which in turn regulates viral replication during the replication cycles of a range of DNA and RNA viruses.\textsuperscript{129–131} Treatment with an antagonist of D4 dopamine receptor such as SKI-417616 (containing a dihydrodibenzothiepine scaffold; Figure 5) in DENV-infected cells inhibited the phosphorylation of ERK, which results in the inhibition of virus replication (especially at the early stage of the replication cycle).\textsuperscript{122} In addition, it inhibited the replication of SINV at 1 or 10 \textmu M concentration,\textsuperscript{122} which suggests that D4 dopamine receptor signalling could be one of the regulatory factors involved in the replication of alphavirus.

Before the degradation of a target mRNA, argonaute (Ago) proteins and microRNAs (miRNAs) along with other co-factors become incorporated into the RNA-induced silencing complex (RISC), which in turn associates with the target mRNA.\textsuperscript{122,133} The association...
between cellular miRNAs, miRNA processing machinery and VEEV replication was shown when a marked decrease in VEEV replication was observed in the absence of Ago2. Acriflavine (ACF; Figure 5)—a mixture of trypanflavine and proflavine—was found to inhibit the association between Ago2 and other co-factors that assist in RNA loading onto the RISC, thereby reducing VEEV replication. Interestingly, ACF demonstrated broad-spectrum antiviral activity against WEEV and EEEV, suggesting that it could act upon a pathway that is conserved among the encephalitic alphaviruses. However, ACF treatment in infected BALB/c mice did not significantly reduce virus replication. This could be due to its short biological half-life, which accounted for the differences between its in vivo and in vitro effects in VEEV infection.

HSP-90, which assists in proper folding of viral proteins and stabilizes these proteins against heat stress, plays an important role in the replication of many DNA and RNA viruses. HSP-90 is involved in the CHIKV RC by interacting with nsP3 and nsP4 to facilitate virus replication. For this reason, HSP-90 inhibitors such as HS-10, SNX-2112 and geldanamycin (Figure 5) were investigated and found to inhibit CHIKV replication.

VEEV CP was known to associate with cellular proteins such as host trafficking proteins (i.e. cellular importin α/β, chromosomal maintenance 1 (CRM1) and nuclear pore complex), which have the unique ability to block the nuclear import of transcription factors required for an antiviral response, and the export of newly synthesized cellular mRNA. Hence, host trafficking proteins are viable targets for antivirals designed specifically to interrupt the interaction between CP and these proteins. Nuclear transport inhibitors such as mifepristone, ivermectin and leptomycin B have been shown to inhibit VEEV replication by altering VEEV CP localization and activity. Of these, leptomycin B, a well-documented CRM1 inhibitor and Streptomyces metabolite, was very potent in restricting the CP to the nucleus, making it unavailable at the cytoplasm to form viable virions.

Since leptomycin B is rather cytotoxic, there is a need to investigate a new generation of CRM1 inhibitors. Hence, a series of selective inhibitors of nuclear export (SINE) compounds, such as KPT-185, KPT-335 (Figure 5) and KPT-350, which are analogues of selinexor, was explored. These compounds confine VEEV CP to the nucleus, leading to a depletion in the amount of cytoplasmic CP (i.e. intracellular CP) and released CP (i.e. extracellular CP), as demonstrated in western blot analyses. This leads to a decrease in virus assembly and/or release of mature virions. Serial passaging of VEEV-infected cells in the presence of KPT-185 resulted in mutations within the nuclear localization and nuclear export signals in the CP (i.e. T41I, K64E or K64M), confirming that this SINE compound exerts its antiviral activity by targeting CP localization.

Bortezomib (Figure 5) is a dipeptidyl boronic acid that specifically and reversibly inhibits the ubiquitin proteasome. As a result, the early stage of the VEEV infectious cycle was affected by bortezomib during the fusion stage, when the VEEV CP was K48 ubiquitinated for proteasomal degradation for the release of the viral RNA. Bortezomib treatment also decreased the multiplication of other virulent New World alphaviruses.

5. Conclusions and perspectives

A number of reported direct-acting and host-targeting inhibitors of alphaviruses have been highlighted, with the emphasis on their mechanisms of action. These include drugs that are already on the market and currently used for the treatment of other diseases, such as doxycycline, phenothiazines, chloroquine, obatoclax, suramin and digoxin, which have been discovered in drug repurposing screens. The challenge here is to improve the potency of these compounds against CHIKV while retaining good drug-like properties. The inhibitory activities of the tested compounds against alphavirus ranged from strong to weak inhibition depending on the type of assay used, with secopregnane steroid glycoside 13 being the strongest inhibitor, with EC50 1.5 and 2 nM against SINV replication and EEEV-induced CPE, respectively, while suramin displayed the weakest activity against SINV-induced CPE, with EC50 141 μM. Despite the selective antiviral activity of direct-acting inhibitors such as favipiravir, CID15997213 and ML336 against the functions of alphavirus elements compared with host cellular targets, the use of direct-acting inhibitors in treatment regimens can lead to the rapid selection of resistant viruses. On the other hand, host-targeting inhibitors such as digoxin, bortezomib, berberine, Ag-126 and SINE compounds represent an alternative approach, and may increase the barrier to resistance and achieve broad-spectrum antiviral coverage against a range of alphaviruses. However, a possible downside is the potential on-target toxicity, as exemplified by digoxin, an inhibitor of the Na+–K+-ATPase ion pump, which shows toxicity at concentrations as low as 1 μM.

Besides developing small-molecule inhibitors as therapy against alphaviruses, other forms of unconventional antiviral therapy, such as RNA interference (RNAi)-based therapy and antiviral immunotherapy, can be considered. Given the ability to specifically silence any gene of interest in the viral RNA, thereby preventing viral proteins from being translated, short interfering RNAs (siRNAs) and miRNAs, which constitute RNAi-based therapy, offer several advantages over conventional drugs as potential therapeutic agents by overcoming patient compliance and drug toxicity issues. As the innate immune system plays a central role in the progression and control of alphavirus infection, small-molecule immunomodulators such as DD264, G10 and 5,6-dimethylxanthene-4-acetic acid, which stimulate expression of antiviral proteins, have also been explored as potential therapeutic agents against alphavirus infection.

With the recent advances in RNAi technology and developments in the characterization of the receptors and pathways of the innate immune system associated with alphavirus infection, it should be possible to develop highly targeted RNAi-based and immunomodulatory therapies for the treatment of alphavirus infections.

Transparency declarations

None to declare.

References

1 Gould EA, Coutard B, Malet H et al. Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control. Antiviral Res 2010; 87: 111–24.
2 Strauss JH, Strauss EG. The alphaviruses—gene expression, replication, and evolution. Microbiol Rev 1994; 58: 491–562.
3 Powers AM, Brault AC, Shirako Y et al. Evolutionary relationships and systematics of the alphaviruses. J Virol 2001; 75: 10118–31.
Review

4. Weaver SC, Winegar R, Manger ID et al. Alphaviruses: population genetics and determinants of emergence. Antiviral Res 2012; 94: 242–57.

5. Suhbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol 2012; 8: 420–9.

6. Wu JQH. Virulence determinants of New World alphaviruses and broad-acting therapeutic strategies. Future Virol 2015; 10: 647–57.

7. Mukhopadhyay S, Zhang W, Gabler S et al. Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure 2006; 14: 63–73.

8. Lescar J, Roussel A, Wien MW et al. The fusin glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 2001; 106: 137–48.

9. Jose J, Snyder JE, Kuhn RJ. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol 2009; 4: 837–56.

10. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J 2009; 11: 65–77.

11. Aperedes AM, Ferreira D, Horton M et al. Conformational changes in Sindbis virions resulting from exposure to low pH and interactions with cells suggest that cell penetration may occur at the cell surface in the absence of membrane fusion. Virology 2004; 324: 373–86.

12. De Groot RJ, Hardy WR, Shirako Y et al. Cleavage-site preferences of Sindbis virus polyproteins containing the non-structural protease. Evidence for temporal regulation of polyprotein processing in vivo. EMBO J 1990; 9: 2631–8.

13. Shirako Y, Strauss JH. Regulation of Sindbis virus RNA replication: uncleaved PI23 and nsP4 function in minus-strand RNA synthesis, whereas cleaved products from PI23 are required for efficient plus-strand RNA synthesis. J Virol 1994; 68: 1874–85.

14. Shi G, Yost SA, Miller MT et al. Structural and functional insights into alphavirus polyprotein processing and pathogenesis. Proc Natl Acad Sci USA 2012; 109: 16534–9.

15. Kaarainen L, Ahola T. Functions of alphavirus nonstructural pro- teins in RNA replication. Prog Nucleic Acid Res Mol Biol 2002; 71: 187–222.

16. Raju R, Huang HV. Analysis of Sindbis virus promoter recognition and determinants of emergence. Molecular and cellular proteomics. J Virol 1990; 65: 2501–10.

17. Hahn CS, Strauss JH. Site-directed mutagenesis of the proposed catalytic amino acids of the Sindbis virus protein polyprotein. J Virol 1990; 64: 3069–73.

18. Tellinghuisen TL, Perera R, Kuhn RJ. In vitro assembly of Sindbis virus core-like particles from cross-linked dimers of truncated and mutant capsid proteins. J Virol 2001; 75: 2810–7.

19. Sefton BM. Immediate glycosylation of Sindbis virus membrane proteins. Cell 1977; 10: 659–68.

20. Logis M, Garoff H. Fusion function of the Semliki Forest virus spike is activated by proteolytic cleavage of the envelope glycoprotein precursor p62. J Virol 1990; 64: 1233–40.

21. Liú N, Brown DT. Transient translocation of the cytoplasmic (endo) domain of a type I membrane glycoprotein into cellular membranes. J Biol Chem 1993; 268: 877–83.

22. Metsikkö K, Garoff H. Oligomers of the cytoplasmic domain of the p62/E2 protein of Semliki Forest virus bind to the nucleocapsid in vitro. J Virol 1990; 64: 4678–83.

23. Garoff H, Sjoberg M, Cheng RH. Budding of alphaviruses. Virus Res 2004; 106: 103–16.

24. Rougeron V, Sam IC, Caron M et al. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. J Clin Virol 2015; 64: 144–52.

25. Reiter P, Fontenille D, Paupy C. Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem? Lancet Infect Dis 2006; 6: 453–4.

26. Parola P, de Lamballerie X, Jourdan J et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006; 12: 1493–9.

27. Naresh Kumar CVM, Sai Gopal DVR. Re-emergence of chikungunya virus in Indian subcontinent. Indian J Virol 2010; 21: 8–17.

28. Aubry M, Teissier A, Roche C et al. Chikungunya outbreak, French Polynesia, 2014. Emerg Infect Dis 2015; 21: 724–6.

29. Morrison TE. Re-emergence of chikungunya virus. J Virol 2014; 88: 11644–7.

30. Higgs S. Chikungunya virus: a major emerging threat. Vector Borne Zoonotic Dis 2014; 14: 535–6.

31. Pulmanassahakul R, Royrakul S, Auevarakul P et al. Chikungunya in Southeast Asia: understanding the emergence and finding solutions. Int J Infect Dis 2011; 15: e671–6.

32. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372: 1231–9.

33. Weaver SC. Arrival of chikungunya virus in the new world: prospects for spread and impact on public health. PLoS Negl Trop Dis 2018; 12: e0002921.

34. Wahid B, Ali A, Rafique S et al. Global expansion of chikungunya virus: mapping the 64-year history. Int J Infect Dis 2017; 58: 69–76.

35. Abdenabi R, Nyets J, Delang L. Towards antivirals against chikungunya virus. Antiviral Res 2015; 121: 59–68.

36. Parashar D, Chelian S. Antiviral perspectives for chikungunya virus. BioMed Res Int 2014; 2014: 631642.

37. Rashad AA, Mahalingam S, Keller PA. Chikungunya virus: emerging targets and new opportunities for medicinal chemistry. J Med Chem 2014; 57: 1147–66.

38. Bhakat S, Solomon MES. Chikungunya virus (CHIKV) inhibitors from natural sources: a medicinal chemistry perspective. J Nat Med 2015; 69: 451–62.

39. Rothan HA, Bahrami H, Mahamed Z et al. A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One 2015; 10: e0126360.

40. Boriskin YS, Leneva IA, Pecheur EI et al. Arbido: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2005; 15: 997–1005.

41. Delogu I, Pastorino B, Baronti C et al. In vitro antiviral activity of arbido against chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011; 90: 99–107.

42. Di Mola A, Peduto A, La Gatta A et al. Structure-activity relationship study of arbido derivatives as inhibitors of chikungunya virus replication. Bioorg Med Chem 2014; 22: 6014–25.

43. Pohjala L, Uut A, Varjak M et al. Inhibitors of alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-based assays. PLoS One 2011; 6: e28923.

44. Wang LH, Rothberg KG, Anderson RGW. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993; 123: 1107–17.

45. Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci USA 2010; 107: 291–6.

46. Chandramohan M, Selvam P, Vivekananthan SC et al. Antimalarial chloroquine metforminophilised into antiviral agent against HIV with four modes of actions. BMC Infect Dis 2012; 12: O21.

47. Khan M, Santhosh SR, Tiwari M et al. Assessment of in vitro prophyactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells. J Med Virol 2010; 82: 817–24.

48. Cassell S, Edwards J, Brown DT. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 1984; 52: 857–64.
49 Helenius A, Marsh M, White J. Inhibition of Semliki Forest virus penetration by lysosomotropic weak bases. J Gen Virol 1982; 58: 47–61.

50 Maeshashi RK, Srikantan V, Bhartiya D. Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice. J Virol 1991; 65: 992–5.

51 De Lambarriere X, Baisson V, Reynier JC et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8: 837–9.

52 Varghese FS, Rauzal K, Hakanen M et al. Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments. Antimicrob Agents Chemother 2016; 61: e02277-16.

53 Gigante A, Caneda ML, Delang L et al. Identification of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as novel inhibitors of chikungunya virus replication. J Med Chem 2014; 57: 4000–8.

54 Delang L, Li C, Tas A et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci Rep 2016; 6: 31819.

55 Decary E, Debarrot C, Ferron F et al. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2′-O-methyltransferase nsP10/NSP16 complex. PLoS Pathog 2011; 7: e1002059.

56 Li C, Guillon J, Rabah N et al. mRNA capping by Venezuelan equine encephalitis virus nsP1: functional characterization and implications for antiviral research. J Virol 2015; 89: 8292–303.

57 Jadav SS, Sinha BN, Hilgenfeld R et al. Thiazolidone derivatives as inhibitors of chikungunya virus. Eur J Med Chem 2015; 99: 172–8.

58 Bassetti M, De Burghgraeve T, Delang L et al. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Res 2013; 98: 12–8.

59 Das PK, Puusepp L, Varghese FS et al. Design and validation of novel chikungunya virus protease inhibitors. Antimicrob Agents Chemother 2016; 60: 7382–95.

60 Postarino BA, Peyrefitte CN, Almeras L et al. Expression and biochemical characterization of nsP2 cysteine protease of chikungunya virus. Virus Res 2008; 131: 293–8.

61 El-Labbad EM, Ismail MA, Abou ELla DA et al. Discovery of novel peptidomimetics as irreversible CHIKV nsP2 protease inhibitors using quantum mechanical-based ligand descriptors. Chem Biol Drug Des 2015; 86: 1518–27.

62 Chung DH, Jonsson CB, Tower NA et al. Discovery of a novel compound with anti-Venezuelan equine encephalitis virus activity that targets the non-structural protein 2. PLoS Pathog 2014; 10: e1004213.

63 Schroeder CE, Yao T, Sotsky J et al. Expression and biochemical characterization of prohibitin as a receptor protein mediating DENV-2 entry into insect cells. Vector Borne Zoonotic Dis 2012; 12: 1093–104.

64 Akhrymuk I, Kulemzin SV, Frolova EI. Evasion of the innate immune response: the Old World alphavirus non-structural protein 2 induces rapid degradation of Rbp1, a catalytic subunit of RNA polymerase II. J Virol 2012; 86: 7180–91.

65 Lucas-Hourani M, Lupan A, Despres P et al. A phenotypic assay to identify chikungunya virus inhibitors targeting the nonstructural protein nsP2. J Biol Screen 2013; 18: 172–9.

66 Furuta Y, Gowan BB, Takahashi K et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2010; 86: 446–54.

67 Julander JG, Smee DF, Morrey JD et al. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 2009; 82: 169–71.

68 Delang L, Segura Guerrero N, Tas A et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014; 69: 2770–84.

69 Mishra P, Kumar A, Mamidi P et al. Inhibition of chikungunya virus replication by 1-[2-(methylbenzimidazol-1-yl)methyl]-2-oxo-indolin-3-ylidine] amino(thiourea)(MBZM-N-IBT). Sci Rep 2016; 6: 20122.

70 Li Y, Wang L, Li S et al. Seco-pregnane steroids target the subgenomic RNA of alphavirus-like RNA viruses. Proc Natl Acad Sci USA 2007; 104: 8083–8.

71 Lee S, Kuhn RJ, Rossmann MG. Probing the potential glycoprotein binding site of Sindbis virus capsid protein with dioxane and model building. Proteins 1998; 33: 311–7.

72 Kim HY, Kuhn RJ, Patkar C et al. Synthesis of dioxane-based antiviral agents and evaluation of their biological activities as inhibitors of Sindbis virus replication. Bioorg Med Chem 2007; 15: 2667–79.

73 Kim HY, Patkar C, Warrier R et al. Design, synthesis, and evaluation of dioxane-based antiviral agents targeted against the Sindbis virus capsid protein. Bioorg Med Chem Lett 2005; 15: 3207–11.

74 Fernandez-Pol JA, Klos DJ, Hamilton PD. Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Antiviral Res 2001; 49: 377–6.

75 Sharma R, Fatma B, Saha A et al. Inhibition of chikungunya virus by picolinate that targets viral capsid protein. Virology 2016; 498: 265–76.

76 Voogd TE, Vansterkenburg LM, Wilting J et al. Recent research on the biological activity of suramin. Pharmacol Rev 1993; 45: 177–203.

77 De Clercq E. Curious discoveries in antiviral drug development: the role of serendipity. Med Res Rev 2015; 35: 698–719.

78 Ho YJ, Wang YM, Lu JW et al. Suramin inhibits chikungunya virus entry and transmission. PLoS One 2015; 10: e0133511.

79 Albulescu JC, van Hoolwerff M, Wolters LA et al. Suramin inhibits chikungunya virus replication through multiple mechanisms. Antiviral Res 2015; 121: 39–46.

80 Henss L, Beck S, Weidner T et al. Suramin is a potent inhibitor of chikungunya and ebola virus cell entry. Virol J 2016; 13: 149.

81 Kuo SC, Wang YM, Ho YJ et al. Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 2016; 134: 89–96.

82 Glennon RA, Hong SS, Dukat M et al. 5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D receptor agonist. J Med Chem 1994; 37: 2828–30.

83 Mainou BA, Ashbrook AW, Smith EC et al. Serotonin receptor agonist 5-nonyloxytryptamine alters the kinetics of reovirus cell entry. J Virol 2015; 89: 8701–12.

84 Chang SY, Bae SJ, Lee MY et al. Chemical affinity matrix-based identification of prohibitin as a binding protein to anti-resorptive sulfonyl amide compounds. Bioorg Med Chem Lett 2011; 21: 727–9.

85 Polier G, Neumann J, Thauaud F et al. The natural anticoagulant compounds rocaalamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 2012; 19: 1093–104.

86 Wintachai P, Wikan N, Kuadkitkan A et al. Identification of prohibitin as a chikungunya virus receptor protein. J Med Virol 2012; 84: 1757–70.

87 Wintachai P, Thauaud F, Basmaidjan C et al. Assessment of flavaglines as potential chikungunya virus entry inhibitors. Microbial Immunol 2015; 59: 129–41.

88 De Clercq E. Milestones in the discovery of antiviral agents: nucleosides and nucleotides. Acta Pharm Sin B 2012; 2: 535–48.

89 Jordheim LP, Durantel D, Zoulim F et al. Advances in the development of DENV-2 entry inhibitors. Virology 2010; 406: 149–61.

90 Emerson V, Holtkotte D, Pfeiffer T et al. Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein. J Virol 2010; 84: 1355–65.

91 Wintachai P, Thauaud F, Basmaidjan C et al. Assessment of flavaglines as potential chikungunya virus entry inhibitors. Microbial Immunol 2015; 59: 129–41.

92 Hoffmann JH, Sidwell RW, Khare GP et al. In vitro effect of 1-(beta-d-ribofuranosyl)-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on deoxyribonuclei
acid and ribonucleic acid viruses. Antimicrob Agents Chemother 1973; 3: 235–41.
93 Brionlant S, Garin D, Scaramuzzino N et al. In vitro inhibition of chikungunya and Semliki Forest viruses by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61: 111–7.
94 Leysens P, Balzarini J, De Clercq E et al. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005; 79: 1943–7.
95 Smee DF, Alaghamandan HA, Kini GD et al. Antiviral activity and mode of action of ribavirin S- sulfamate against Semliki Forest virus. Antiviral Res 1988; 10: 253–62.
96 De Clercq E, Luczak M. Fluoromimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci 1975; 17: 187–94.
97 De Clercq E, Bernaerts R, Fulmer Shealy Y et al. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochim Pharmacol 1990; 39: 319–25.
98 Julander JG, Bowen RA, Rao JR et al. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 2008; 80: 309–15.
99 Mahy BWJ, Cox NJ, Armstrong SJ et al. Manipulation of influenza virus in the presence of coryzatine, an inhibitor of cellular RNA synthesis. Nat New Biol 1973; 24: 172–4.
100 Philipson L, Wall R, Glickman G et al. Addition of polyadenylate sequences to virus-specific DNA during adenoavirus replication. Proc Natl Acad Sci USA 1971; 68: 2806–9.
101 Witek R, Kobiet H, Menn A et al. The effect of cordycepin on the multiplication of Semliki Forest virus and on polyanhydrolysis of viral RNA. Arch Virol 1977; 54: 95–106.
102 Planterose DN. Antiviral and cytotoxic effects of mycophenolic acid. J Gen Virol 1969; 4: 629–30.
103 Khan M, Dhanwani R, Patro JK et al. Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 2011; 89: 1–8.
104 Molina S, Sanz MA, Madan V et al. Differential inhibition of cellular and Sindbis virus translation by brefeldin A. Virology 2007; 363: 430–6.
105 Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic cells by (-)-carbodine. J Virol 2010; 84: 5155–63.
106 Ashbrook AW, Lentscher AJ, Zumora PF et al. Antagonism of the sodium-potassium ATPase impairs chikungunya virus infection. MBio 2016; 7: e00693-16.
107 Blix HS, Viktil KK, Moger TA et al. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada) 2010; 8: 50–8.
108 Peng WP, Peltier DC, Larsen MJ et al. Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses. J Infect Dis 2009; 199: 950–7.
111 Sindac JA, Yestreskpy BD, Barraza SJ et al. Novel inhibitors of neurotropic alphavirus replication that improve host survival in a mouse model of acute viral encephalitis. J Med Chem 2012; 55: 3535–45.
112 Sindac JA, Barraza SJ, Dobry CJ et al. Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication. J Med Chem 2013; 56: 9222–41.
a mixture of acriflavine and guanosine, a potential antitumour agent. *Xenobiotica* 2005; 35: 755–73.

136 Hu J, Toft DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. *EMBO* J 1997; 16: 59–68.

137 Hu J, Anselmo D. *In vitro* reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by HSP90. *J Virol* 2000; 74: 11447–55.

138 Rathore AP, Haystead T, Das PK et al. Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. *Antiviral Res* 2014; 103: 7–16.

139 Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? *Antiviral Res* 2012; 95: 202–6.

140 Lundberg L, Pinkham C, Baer A et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication. *Antiviral Res* 2013; 100: 662–72.

141 Lundberg L, Pinkham C, de la Fuente C et al. Selective inhibitor of nuclear export (SINE) compounds alter New World alphavirus capsid localization and reduce viral replication in mammalian cells. *PLoS Negl Trop Dis* 2016; 10: e0005122.

142 Jackson G, Einsele H, Moreau P et al. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. *Cancer Treat Rev* 2005; 31: 591–602.

143 Amaya M, Keck F, Lindquist M et al. The ubiquitin proteasome system plays a role in Venezuelan equine encephalitis virus infection. *PLoS One* 2015; 10: e0124792.

144 Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. *Gene Ther* 2006; 13: 532–40.

145 Sali TM, Pryke KM, Abraham J et al. Characterization of a novel human-specific sting agonist that elicits antiviral activity against emerging alphaviruses. *PLoS Pathog* 2015; 11: e1005324.

146 Lucas-Hourani M, Dauzonne D, Jorda P et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. *PLoS Pathog* 2013; 9: e1003678.

147 Snyder AJ, Mukhopadhyay S. The alphavirus E3 glycoprotein functions in a clade-specific manner. *J Virol* 2012; 86: 13609–20.

148 De Lamballerie X, Ninove L, Charrel RN. Antiviral treatment of chikungunya virus infection. *Infect Disord Drug Targets* 2009; 9: 101–4.

149 Delaguy I, de Lamballerie X. Chikungunya disease and chloroquine treatment. *J Med Virol* 2011; 83: 1058–9.